Drugs / Sorivudine
Sorivudine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00652184 | Mar 2008 → Jun 2009 | herpes zoster, postherpetic neuralgia | aRigen Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00000953 | ? → Sep 1996 | HIV infectious disease, chickenpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00002358 | — | HIV infectious disease, chickenpox | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sorivudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000953 ↗ |
| Known as | Bravavir | ChEMBL registry synonym — accepted as the source's own label CHEMBL70046 ↗ |
| Known as | brovavir | “oral sorivudine (brovavir)” NCT00000953 ↗ |
| Known as | BV-araU | “To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.” NCT00002358 ↗ |
| Known as | SO 32,756 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70046 ↗ |
| Known as | Sorivudina | ChEMBL registry synonym — accepted as the source's own label CHEMBL70046 ↗ |
| Known as | SQ 32,756 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70046 ↗ |
| Known as | YN-72 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70046 ↗ |
| Modality | Small molecule | — CHEMBL70046 ↗ |
| Route | Oral | “oral sorivudine (brovavir) and oral acyclovir” NCT00000953 ↗ |